Scientists have harnessed the power of artificial intelligence to uncover a groundbreaking antibiotic named “abaucin,” designed to combat the formidable and drug-resistant bacterium Acinetobacter baumannii. By specifically targeting this bacteria, the novel antibiotic significantly reduces the risk of drug resistance development, paving the way for a cost-effective and efficient approach to discovering antibiotics.
Furthermore, this innovative process has the potential to expedite the discovery of other urgently needed antibiotics.
A collaborative effort between McMaster University and the Massachusetts Institute of Technology has employed artificial intelligence techniques to identify a new antibiotic capable of combating a lethal drug-resistant pathogen that primarily affects vulnerable patients in hospitals.
Additionally, this approach holds the promise of expediting the discovery of other antibiotics to effectively treat various challenging bacterial infections.
The motivation behind this research stemmed from the urgent demand for novel drugs to combat Acinetobacter baumannii, which the World Health Organization has classified as one of the most hazardous antibiotic-resistant bacteria worldwide. This elusive pathogen is notoriously difficult to eradicate and can cause life-threatening conditions such as pneumonia, meningitis, and wound infections.
Lead author Jonathan Stokes, an assistant professor in the Department of Biochemistry & Biomedical Science at McMaster University, spearheaded the identification of a new antibacterial compound to address the Acinetobacter baumannii pathogen.
Acinetobacter baumannii is commonly found in hospital environments, where it can persist on surfaces for extended periods. The pathogen possesses the ability to acquire DNA from other bacterial species in its surroundings, including genes associated with antibiotic resistance.
In a study published on May 25 in the journal Nature Chemical Biology, the researchers detailed their use of an artificial intelligence algorithm to predict new structural classes of antibacterial compounds. Through this method, they successfully discovered a novel antibacterial compound, which they named abaucin.
Traditional screening methods for identifying antibiotics effective against Acinetobacter baumannii have proved challenging. These conventional approaches are time-consuming, expensive, and limited in scope.
In contrast, modern algorithmic approaches have the capacity to analyze hundreds of millions, if not billions, of molecules with potential antibacterial properties.
Jonathan Stokes, the lead author of the study and an assistant professor in McMaster’s Department of Biomedicine & Biochemistry, asserts, “This work validates the benefits of machine learning in the search for new antibiotics.” Stokes collaborated with James J. Collins, a professor of medical engineering and science at MIT, as well as McMaster graduate students Gary Liu and Denise Catacutan in conducting this groundbreaking research.
Gary Liu, a graduate student in the Department of Biochemistry & Biomedical Science at McMaster University and co-author of the paper, played a vital role in this study.
Stokes further emphasizes, “Using AI, we can rapidly explore vast regions of chemical space, significantly increasing the chances of discovering fundamentally new antibacterial molecules.” Stokes is associated with McMaster’s Global Nexus School for Pandemic Prevention and Response.
Collins, the Life Sciences faculty lead at the MIT Abdul Latif Jameel Clinic for Machine Learning in Health, states, “AI approaches to drug discovery are here to stay and will continue to be refined. We know algorithmic models work, now it’s a matter of widely adopting these methods to discover new antibiotics more efficiently and less expensively.”
One notable aspect of abaucin is its targeted nature, exclusively focusing on Acinetobacter baumannii. This promising characteristic reduces the likelihood of rapid drug resistance development, potentially leading to more precise and effective treatments.
Denise Catacutan, a graduate student in the Department of Biochemistry & Biomedical Science at McMaster University and co-author of the paper, also played a crucial role in this research.
Conventional antibiotics are typically broad-spectrum, indiscriminately killing both harmful and beneficial bacteria in the body, thereby disrupting the gut microbiome and leaving patients susceptible to severe infections, including C. difficile.
Stokes comments, “We know broad-spectrum antibiotics are suboptimal, and that pathogens have the ability to evolve and adjust to every trick we throw at them. AI methods afford us the opportunity to vastly increase the rate at which we discover new antibiotics, and we can do it at a reduced cost. This is an important avenue of exploration for new antibiotic drugs.”
For further information on this groundbreaking discovery, please refer to “AI Helps Find New Antibiotic Drug to Combat Drug-Resistant Infections.”
Reference: “Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii” by Gary Liu, Denise B. Catacutan, Khushi Rathod, Kyle Swanson, Wengong Jin, Jody C. Mohammed, Anush Chiappino-Pepe, Saad A. Syed, Meghan Fragis, Kenneth Rachwalski, Jakob Magolan, Michael G. Surette, Brian K. Coombes, Tommi Jaakkola, Regina Barzilay, James J. Collins, and Jonathan M. Stokes, 25 May 2023, Nature Chemical Biology. DOI: 10.1038/s41589-023-01349-8
Note: By using this site, you consent to the use of Google Analytics and related cookies throughout the TrendMD network (widget, website, blog). Learn more.
Table of Contents
Frequently Asked Questions (FAQs) about Antibiotic discovery
What is the significance of artificial intelligence in antibiotic discovery?
Artificial intelligence (AI) plays a crucial role in antibiotic discovery by enabling scientists to rapidly explore vast chemical spaces and predict new structural classes of antibacterial molecules. This significantly increases the chances of discovering novel antibiotics more efficiently and cost-effectively.
How does AI help in combating drug-resistant bacteria?
AI algorithms can analyze large datasets and identify potential antibacterial compounds that specifically target drug-resistant bacteria, such as Acinetobacter baumannii. By focusing on these specific pathogens, AI helps reduce the risk of rapid drug resistance development and enables the development of more precise and effective treatments.
Why is the discovery of targeted antibiotics important?
The discovery of targeted antibiotics is crucial because it allows for more precise treatment of bacterial infections. Unlike broad-spectrum antibiotics, which kill both harmful and beneficial bacteria, targeted antibiotics focus only on the specific pathogen, minimizing disruptions to the body’s microbiome and reducing the risk of developing secondary infections.
What are the limitations of conventional antibiotic discovery methods?
Conventional antibiotic discovery methods are often time-consuming, costly, and limited in scope. They rely on labor-intensive screening processes that can be inefficient in identifying novel compounds. In contrast, AI-driven approaches can quickly analyze vast numbers of molecules and predict their antibacterial properties, accelerating the discovery process.
How does AI contribute to the fight against antibiotic resistance?
AI contributes to the fight against antibiotic resistance by aiding in the discovery of new antibiotics that target drug-resistant bacteria. By discovering novel compounds that can overcome resistant mechanisms, AI helps address the challenge of evolving pathogens and provides potential solutions to combat antibiotic resistance effectively.
Can AI revolutionize other areas of healthcare?
Yes, AI has the potential to revolutionize various areas of healthcare beyond antibiotic discovery. It can be applied in disease diagnosis, drug development, personalized medicine, and medical imaging analysis, among other fields. AI’s ability to analyze vast amounts of data and recognize patterns opens up new possibilities for improving patient care and advancing medical research.
More about Antibiotic discovery
- McMaster University: Link to McMaster University’s official website
- Massachusetts Institute of Technology (MIT): Link to MIT’s official website
- World Health Organization (WHO): Link to WHO’s official website
- Nature Chemical Biology: Link to the journal’s website
- “Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii”: Link to the research paper
7 comments
Wow, AI is doing some seriously cool stuff! Discovering new antibiotics to fight those nasty superbugs? That’s amazing!
This is the kind of breakthrough we’ve been waiting for! Finally, a targeted antibiotic that can tackle drug-resistant bacteria. The potential impact is huge!
AI + antibiotics = a winning combo! This could be a game-changer in the fight against deadly infections. Can’t wait to see more advancements in this field.
Kudos to the researchers for using AI to speed up the discovery of antibiotics. It’s about time we find more effective ways to combat these challenging bacteria.
I’m fascinated by the power of AI in drug discovery. Being able to explore vast chemical space and find new antibacterial molecules? Mind-blowing!
Finally, a ray of hope in the battle against drug-resistant bacteria. This targeted antibiotic could save countless lives. Science for the win!
The future is here! AI is revolutionizing the healthcare industry, and this breakthrough in antibiotic discovery is just the beginning. Exciting times ahead!